- #15 on 7/31 (day before)
Corcept reported $35.6 million in sales and adjusted income of 13 cents per share, up a respective 80% and 333% vs. the year-earlier period. Analysts had called for $32.5 million in sales. Adjusted income expectations were not immediately available. Income per share of 10 cents beat analysts' views for 7 cents.
Corcept is continuing to enroll a Phase 2 trial for a drug to treat Cushing's syndrome, which results when the body is exposed to high levels of the hormone cortisol for a long time. Symptoms include abdominal obesity, high blood pressure, stretch marks, weak muscles and bones, and acne.
It also has two cortisol modulators entering Phase 1 trials in the near future. One will be combined with Xtandi, a drug Pfizer (PFE) acquired when it bought Medivation last year, in a population of patients with prostate cancer.
Enrollment is also ongoing in a Phase 1/Phase 2 trial of a drug combined with Celgene's (CELG) Abraxane to treat patients with solid-tumor cancers.
No comments:
Post a Comment